Literature DB >> 19236729

Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice.

Thierry Deltheil1, Kenji Tanaka, Christelle Reperant, René Hen, Denis J David, Alain M Gardier.   

Abstract

Preclinical data support the view that brain-derived neurotrophic factor (BDNF) and serotonergic systems regulate circuits involved in affective disorders. The present study examined neurochemical and behavioural consequences of an acute intrahippocampal injection of BDNF combined with an antidepressant by using in-vivo intracerebral microdialysis in the ventral hippocampus (vHi) in conscious mice and behavioural paradigms predictive of antidepressant and anxiolytic-like effects [the mouse forced swim test (FST), the open-field (OF) paradigm and the elevated plus maze (EPM)]. Neurochemical data revealed that BDNF (100 ng) potentiated the effects of the systemic administration of a serotonin selective reuptake inhibitor (SSRI; paroxetine 4 mg/kg i.p.) and that of a locally applied citalopram perfusion on dialysate 5-HT levels in the vHi. These neurochemical changes correlated with behavioural data since, in the FST, antidepressant-like activity of paroxetine as measured on swimming behaviour was potentiated by BDNF. These data suggest an interesting synergy between BDNF and SSRI on antidepressant-like activity. Furthermore, in both the OF and EPM paradigms BDNF induced an anxiogenic-like activity, whereas paroxetine prevented this effect. Finally, the neurochemical and behavioural effects of BDNF on the serotonergic system might occur at both pre- and post-synaptic levels since by using in-situ hybridization, we showed that TrkB-R mRNA was expressed in the hippocampus and the dorsal raphe nucleus in adult mice. Taken together the neurochemical and behavioural effects of BDNF suggest that these behavioural changes were mediated by increases in 5-HT neurotransmission in vHi. Thus a BDNF+SSRI combination may offer new alternatives to treat mood disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19236729     DOI: 10.1017/S1461145709000017

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  14 in total

1.  Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models.

Authors:  Heath D Schmidt; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2010-08-04       Impact factor: 7.853

2.  Variant brain-derived neurotrophic factor (Valine66Methionine) polymorphism contributes to developmental and estrous stage-specific expression of anxiety-like behavior in female mice.

Authors:  Kevin G Bath; Jocelyn Chuang; Joanna L Spencer-Segal; Dima Amso; Margaret Altemus; Bruce S McEwen; Francis S Lee
Journal:  Biol Psychiatry       Date:  2012-05-01       Impact factor: 13.382

3.  Viral-mediated overexpression of the Myelin Transcription Factor 1 (MyT1) in the dentate gyrus attenuates anxiety- and ethanol-related behaviors in rats.

Authors:  Amine Bahi; Jean-Luc Dreyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-16       Impact factor: 4.530

4.  New insights into BDNF signaling: relevance to major depression and antidepressant action.

Authors:  Ilan A Kerman
Journal:  Am J Psychiatry       Date:  2012-11       Impact factor: 18.112

5.  Associations between parenting behavior and anxiety in a rodent model and a clinical sample: relationship to peripheral BDNF levels.

Authors:  R Dalle Molle; A K Portella; M Z Goldani; F P Kapczinski; S Leistner-Segal; S Leistner-Segala; G A Salum; G G Manfro; P P Silveira
Journal:  Transl Psychiatry       Date:  2012-11-20       Impact factor: 6.222

6.  Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression.

Authors:  J-P Guilloux; G Douillard-Guilloux; R Kota; X Wang; A M Gardier; K Martinowich; G C Tseng; D A Lewis; E Sibille
Journal:  Mol Psychiatry       Date:  2011-09-13       Impact factor: 15.992

7.  Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains.

Authors:  Cristina S Benton; Brooke H Miller; Sean Skwerer; Oscar Suzuki; Laura E Schultz; Michael D Cameron; J S Marron; Mathew T Pletcher; Tim Wiltshire
Journal:  Psychopharmacology (Berl)       Date:  2011-11-24       Impact factor: 4.530

8.  BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities.

Authors:  G Quesseveur; D J David; M C Gaillard; P Pla; M V Wu; H T Nguyen; V Nicolas; G Auregan; I David; A Dranovsky; P Hantraye; R Hen; A M Gardier; N Déglon; B P Guiard
Journal:  Transl Psychiatry       Date:  2013-04-30       Impact factor: 6.222

9.  Antidepressant activity: contribution of brain microdialysis in knock-out mice to the understanding of BDNF/5-HT transporter/5-HT autoreceptor interactions.

Authors:  Alain M Gardier
Journal:  Front Pharmacol       Date:  2013-08-08       Impact factor: 5.810

10.  Oxidative imbalance and anxiety disorders.

Authors:  Krolow R; Arcego D M; Noschang C; Weis S N; Dalmaz C
Journal:  Curr Neuropharmacol       Date:  2014-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.